MedTrace Logo

Role of suPAR in Periodontitis and CVD

NCT04335344 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 326

Last updated 2020-04-07

No results posted yet for this study

Summary

soluble urokinase-type plasminogen activator receptor (suPAR) plays a key role in endothelial function and may be a link for the known interaction of periodontitis and cardiovascular disease (CVD). The investigators compared the impact of gingival health, periodontitis (CP), CHD or of both diseases (CP+CHD) on saliva and serum suPAR levels.

Conditions

  • Metabolic Disturbance
  • Periodontal Diseases

Interventions

OTHER

Observation of suPAR plasma and salivary levels

Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease

Sponsors & Collaborators

  • University of Catania

    collaborator OTHER

  • University of Messina

    lead OTHER

Principal Investigators

  • Giovanni Matarese · University of Messina

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-15
Primary Completion
2018-09-21
Completion
2020-02-25

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04335344 on ClinicalTrials.gov